Arcturus Therapeutics Holdings Inc.
ARCT Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$9.84
KIRA · Stoqly’s AI analyst, in plain words
- Arcturus Therapeutics Holdings Inc. had $82.0M of revenue in fiscal 2025, down 46.1% on the year before. Over five years, revenue changed +53.8% a year on average.
- Its operating margin was −93.0%, down 30.2 pts: of every 100 in sales, about −93 is left after running the business.
- Arcturus Therapeutics Holdings Inc. lost $65.8M in fiscal 2025.
- Free cash flow was −$74.5M in fiscal 2025, −90.8% of revenue.
Market cap
$280M
P/E
—
Revenue
$82.0M
Net income
−$65.8M
Free cash flow
−$74.5M
Operating margin
−93.0%
Arcturus Therapeutics Holdings Inc. in 30 seconds · fiscal 2025
Are sales growing?
−46.1%
No. Sales fell 46.1% last year.
Does it make a profit?
−80.2%
No. It lost money last year.
Does profit turn into cash?
−90.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Arcturus Therapeutics Holdings Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Arcturus Therapeutics Holdings Inc.
- CIK
- 0001768224
Arcturus Therapeutics Holdings Inc. · ARCT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $12.4M | $206M | $167M | $152M | $82.0M |
| Revenue growth | 29.6% | 1,566.8% | −19.0% | −8.7% | −46.1% |
| Operating margin | −1,641.3% | 5.9% | −46.9% | −62.8% | −93.0% |
| Net income | −$204M | $9.3M | −$29.7M | −$80.9M | −$65.8M |
| Net margin | −1,648.0% | 4.5% | −17.8% | −53.1% | −80.2% |
| Diluted EPS | −$7.74 | $0.35 | −$1.12 | −$3.00 | −$2.40 |
| Cash | |||||
| Cash from operations | −$135M | $32.0M | −$18.1M | −$59.7M | −$74.3M |
| Capital expenditure | $3.4M | $7.7M | $2.9M | $0.6M | $0.2M |
| Free cash flow | −$138M | $24.3M | −$21.0M | −$60.4M | −$74.5M |
| FCF margin | −1,120.2% | 11.8% | −12.6% | −39.7% | −90.8% |
| Share count change | 29.6% | 2.9% | −1.7% | 1.4% | 1.4% |
| Debt and strength | |||||
| Cash and short-term investments | $370M | $392M | $292M | $237M | $231M |
| Debt incl. finance leases | $15.3M | $60.7M | — | — | — |
| Shareholders' equity | $228M | $270M | $279M | $241M | $214M |
| Net debt / EBITDA | — | −24.2x | — | — | — |
| Current ratio | 3.8x | 3.2x | 4.7x | 4.7x | 6.6x |
| Returns and quality | |||||
| Return on equity | −65.2% | 3.8% | −10.8% | −31.2% | −28.9% |
| Return on tangible equity | −89.2% | 3.5% | −10.7% | −33.6% | −30.7% |
| Piotroski F-score | 2 | 5 | 3 | 2 | 1 |
| Altman Z'' | −0.2 | 3.3 | 2.6 | 0.9 | 0.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Arcturus Therapeutics Holdings Inc. · ARCT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.84 a share, the company is worth $280M.
Source: SEC EDGAR XBRL filings (CIK 0001768224). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.